top of page
Screenshot 2025-03-17 at 4.17.24 PM.png
  • LinkedIn

Paul R Billings

MD, PhD

Dr. Paul Billings helps transform breakthrough healthcare innovations into enduring healthcare companies.

​

Over three decades, Dr. Billings has helped translate scientific discoveries into commercially successful products across diagnostics, maternal and pediatric health, precision medicine, and biotechnology. His experience spans venture-backed startups, publicly traded companies, and global healthcare organizations, providing expertise across the full continuum of commercialization, from product development and regulatory strategy to reimbursement, adoption, and enterprise scale.

​

As Chief Medical Officer at Natera, he helped drive the adoption of non-invasive prenatal testing (NIPT), fundamentally reshaping maternal-fetal screening. He later served as Chief Medical Officer at Life Technologies through its acquisition by Thermo Fisher Scientific, gaining extensive experience in scaling healthcare technologies within global markets.

​

Having served as CEO of venture-backed companies and held senior leadership roles at Johnson & Johnson, Quest Diagnostics, and Labcorp, Dr. Billings brings founders practical guidance on building companies capable of achieving broad clinical adoption and long-term commercial success.

Select Investments

These investments were made independently and are separate from Fund I's portfolio.

EXIT

EXIT

EXIT

EXIT

EXIT

EXIT

EXIT

SAN FRANCISCO, CA, USA  |

fractal@4pedcapital.com    |

© All Rights Reserved 2026

Fractal Pediatric Capital (FPC) is a website operated by Fractal Pediatric Capital, LLC. By accessing this site and any pages hereof, you agree to be bound by the Terms of Service. FPC does not make investment recommendations, and no communication through this website or otherwise should be construed as a recommendation for any offer of a security referenced on this website or otherwise. Companies or individuals providing information on this site are solely responsible for their content. All investors in FPC Funds must be accredited investors. Investing in private placements requires high tolerance for risk and illiquidity, and investors must be able to afford to lose their entire investment. Information about any securities offering should not be considered complete and is qualified by the full offering documents corresponding to the financing. The information contained here or in any correspondence or attachment hereto may include forward-looking statements, estimates, projections and/or representations. To the fullest extent permissible by law, neither FPC, LLC. nor its funds; nor any of their managers or non-managing members, employees, representatives, or agents make any representation or warranty, express or implied, as to the accuracy, completeness or definitiveness of this information, and nothing contained herein shall be relied upon as a representation as to past or future performance. We are not a registered broker, dealer, investment advisor, investment manager or funding portal. FPC, LLC and FPC Managing Member do not give investment advice, provide analysis or recommendations. *IRS Circular 230 Disclosure: To ensure compliance with requirements imposed by the IRS, we inform you that any tax advice contained in this communication (including any attachments) was not intended or written to be used and cannot be used, for the purpose of (i) avoiding any tax penalty or (ii) promoting, marketing or recommending to another party any transaction or matter addressed herein.

bottom of page